Premium
Antitumour potential of pollen extract on lewis lung carcinoma implanted intraperitoneally in syngeneic mice
Author(s) -
Furusawa E.,
Chou S. C.,
Hirazumi A.,
Melera A.
Publication year - 1995
Publication title -
phytotherapy research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.019
H-Index - 129
eISSN - 1099-1573
pISSN - 0951-418X
DOI - 10.1002/ptr.2650090405
Subject(s) - lewis lung carcinoma , cytotoxic t cell , pharmacology , cisplatin , methotrexate , hyperplasia , cytotoxicity , vincristine , pollen , chemistry , cancer research , medicine , chemotherapy , biology , immunology , pathology , cancer , botany , cyclophosphamide , biochemistry , in vitro , metastasis
A defined pollen extract of selected plants has been reported to possess some pharmacological activities on chronic prostatis or benign prostatic hyperplasia. This paper describes the antitumour potential of the water soluble fraction (Cernitin T60) of pollen extract against Lewis lung carcinoma implanted intraperitoneally in syngeneic mice. Cernitin T60 was not cytotoxic in cell cultures at concentrations up to 2.5 mg/mL, while it is significantly prolonged the life‐span of mice carrying the tumour without any apparent side effects at 0.5 g/kg. In addition, Cernitin T60 demonstrated beneficial therapeutic effects in an additive fashion on the life‐span of mice when it was combined with standard cytotoxic antitumour drugs such as adriamycin, cisplatin, vincristine, methotrexate, fluorouracil, or thioguanine. The antitumour potential of Cernitin T60 was completely abolished by treatment with inhibitors of macrophage functions (2‐chloroadenosine or carrageenan), but not with a T‐cell inhibitor (cyclosporin A). Cernitin T60 appears to be a potent immunostimulator of macrophages.